U031 - Update on Cutaneous Reactions to Targeted and Immune Cancer Therapy
Saturday, February 17; 7:30 AM - 8:30 AM
Following this course, the attendee should be able to:
- Diagnose and treat cutaneous toxicities to targeted and immune cancer therapies.
- Recognize potential correlations between cutaneous toxicities and tumor response.
- Use a team-based approach to manage cutaneous toxicities.
This session will focus on updates in cutaneous toxicities to targeted and immune cancer therapy including BRAF inhibitors, EGFR inhibitors, and immune checkpoint inhibitors. This is a rapidly evolving field in both breadth of disease as well as management options, and this session is geared to the practicing clinician. Also, the significance of cutaneous toxicities will be reviewed including associations with increased tumor response.
This activity has been approved by the American Board of Dermatology (ABD) for up to 10 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.
- Patel, Anisha, MD: no financial relationships exist with commercial interests.
Saturday, February 17
Dr. Patel / Update on Cutaneous Reactions to Targeted and Immune Cancer Therapy